IL-33 improves the suppressive potential of regulatory T cells in patients with type 1 diabetes

Monika Ryba-Stanisławowska; Laura Buksa; Agnieszka Brandt; Ulana Juhas; Małgorzata Myśliwiec

doi:10.1016/j.diabres.2017.04.011

IL-33 improves the suppressive potential of regulatory T cells in patients with type 1 diabetes

Diabetes Res Clin Pract. 2017 Jun:128:67-73. doi: 10.1016/j.diabres.2017.04.011. Epub 2017 Apr 13.

Authors

Monika Ryba-Stanisławowska¹, Laura Buksa², Agnieszka Brandt³, Ulana Juhas², Małgorzata Myśliwiec³

Affiliations

¹ Department of Immunology, Medical University of Gdańsk, Poland. Electronic address: akinomab@gumed.edu.pl.
² Department of Immunology, Medical University of Gdańsk, Poland.
³ Clinic of Pediatrics, Department of Diabetology and Endocrinology, Medical University of Gdańsk, Poland.

PMID: 28448894
DOI: 10.1016/j.diabres.2017.04.011

Abstract

Aims: The presented study was aimed to analyze the influence of IL-33 on regulatory T cells (Tregs) suppressive potential in patients with type 1 diabetes.

Methods: We analyzed the ability of IL-33 treated Tregs to inhibit the production of IFN-γ by effector T lymphocytes in an in vitro co-culture. The study group consisted of 22 patients with type 1 diabetes and 12 age and sex-matched healthy individuals.

Results: Our findings revealed that in vitro IL-33 treatment of Tregs derived from patients with type 1 diabetes resulted in quantitative as well as qualitative changes in this cell population, confirming immunoregulatory features of IL-33.

Conclusion: IL-33 could be considered as a potential therapeutic tool in adoptive therapies of type 1 diabetes.

Keywords: Diabetes type 1; IL-33; Regulatory T cells.

MeSH terms

Adolescent
Diabetes Mellitus, Type 1 / metabolism*
Female
Humans
Interleukin-33 / genetics*
Male
T-Lymphocytes, Regulatory / metabolism*

Substances

IL33 protein, human
Interleukin-33